Clinical Trials for Mesothelioma Patients: Bortezomib Trial Description

Read the description for the current clinical trial being conducted to study the effects of Bortezomib for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, the clinical trials are not being conducted in the United States.

Detailed Description:
Primary Objectives
• Assess the clinical efficacy of Bortezomib based on the evaluation of objective tumor response rate.

Secondary Objectives
• Assess additional clinical efficacy of Bortezomib based on the evaluation of time to early disease progression and median overall 2-year survival rate. • Assess safety and toxicity in these patients. • Assess quality of life using the Lung Cancer Symptom Score.

Outline:
This is a multicenter study. Patients are stratified according to current treatment (first-line vs second-line). Patients receive Bortezomib IV on days 1, 8, 15, and 22. Treatment repeats every 5 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients exhibiting objective response or stable disease by week 20, may continue treatment at the discretion of the investigator until evidence of disease progression. Quality of life is assessed periodically. After completion of study treatment, patients are followed for up to 2 years.

Courtesy of ClinicalTrials.gov,

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney